Gyre Therapeutics (GYRE) Change in Cash (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Change in Cash of $431000.0 for Q1 2026, down 86.66% year-over-year from $3.2 million in Q1 2025, and up 112.94% quarter-over-quarter from -$3.3 million in Q4 2025.
Gyre Therapeutics (GYRE) Change in Cash (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Change in Cash for 17 consecutive years, with $431000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash fell 86.66% year-over-year to $431000.0; the TTM figure through Mar 2026 stood at $22.5 million (up 252.35% YoY), while the FY2025 annual figure was $25.3 million, up 216.41% from the prior year.
- Change in Cash improved to $431000.0 in Q1 2026 per GYRE's latest filing, from -$3.3 million in the prior quarter.
- Across five years, Change in Cash topped out at $40.6 million in Q2 2022 and bottomed at -$52.3 million in Q3 2022.
- Historically, Change in Cash has averaged $429294.1 across 5 years, with a median of $431000.0 in 2026.
- Annual changes were most pronounced in 2022 — Change in Cash slumped 261.62% — and 2025, when it jumped 1793.07%.
- Gyre Therapeutics' Change in Cash stood at $16.2 million in 2022, then tumbled by 54.22% to $7.4 million in 2023, then slumped by 154.55% to -$4.1 million in 2024, then rose by 17.79% to -$3.3 million in 2025, then soared by 112.94% to $431000.0 in 2026.
- Business Quant data shows GYRE's Change in Cash at $431000.0 in Q1 2026, -$3.3 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -6.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.34 Mn |
| Mar 31, 2026 | 431,000.00 |
| Dec 31, 2025 | -3.33 Mn |
| Sep 30, 2025 | 3.91 Mn |
| Jun 30, 2025 | 21.45 Mn |
| Mar 31, 2025 | 3.23 Mn |
| Dec 31, 2024 | -4.05 Mn |
| Sep 30, 2024 | -231,000.00 |
| Jun 30, 2024 | -13.69 Mn |
| Mar 31, 2024 | -3.72 Mn |
| Dec 31, 2023 | 7.43 Mn |
| Sep 30, 2023 | 2.35 Mn |
| Jun 30, 2023 | -4.42 Mn |
| Mar 31, 2023 | 2.97 Mn |
| Dec 31, 2022 | 16.23 Mn |
| Sep 30, 2022 | -52.30 Mn |
| Jun 30, 2022 | 40.58 Mn |
| Mar 31, 2022 | -9.53 Mn |
| Dec 31, 2021 | -14.81 Mn |
| Sep 30, 2021 | -14.46 Mn |